After Medline's IPO, A $10+ Billion Wound Care Reset Is Underway – and MediWound May Be Uniquely Positioned

As reimbursement tightens and capital returns, clinically validated wound care assets are becoming scarce – and strategically valuable

One corner of healthcare quietly ballooned from a roughly $250 million Medicare market into a more than $13 billion one in just over five years. It did so largely without new drugs, limited clinical validation, and minimal regulatory friction. Now, the incentives that fueled that expansion are being unwound – and the entire wound care landscape is being forced to reset.

This inflection point is colliding with a second, equally important development: capital is flowing back into healthcare at scale. In December 2025, Medline (Nasdaq: MDLN) went public in the largest IPO of the year, raising $6.26 billion at a valuation exceeding $50 billion. This IPO signals that public markets see advanced wound care as an investable growth category – and when a dominant player strengthens its balance sheet to compete more aggressively, it raises the bar for what ‘defensible’ looks like across the segment.

Together, these forces – reimbursement tightening and renewed capital discipline – are reshaping how large healthcare companies evaluate wound care assets. In the process, products that sit at critical bottlenecks in care and are supported by rigorous clinical evidence are becoming increasingly scarce. MediWound (Nasdaq: MDWD) is developing one such asset.

From Volume to Validation

For much of the past decade, growth in wound care was driven by volume rather than validation. Cellular and tissue-based products, including skin substitutes and grafts, flourished under favorable Medicare reimbursement. According to CMS, Medicare Part B spending on these products rose from approximately $256 million in 2019 to more than $13 billion in 2025 – a dramatic increase that far outpaced growth in patient volumes.

Much of this expansion came from products that entered the market with limited clinical evidence, often through lower-barrier regulatory pathways. But that model is no longer sustainable. CMS has announced and implemented significant payment-policy changes for 2026 aimed at improving payment accuracy and curbing excessive spending, while Medicare Administrative Contractors continue to reassess coverage standards for skin substitutes.

In practical terms, reimbursement is shifting away from “easy-to-launch” products toward those that can demonstrate safety and effectiveness through prospective clinical trials. Higher-barrier FDA pathways—such as NDAs, BLAs, and PMAs—are increasingly aligned with where reimbursement durability is heading. Products lacking robust clinical validation may still exist, but many now face reduced payment levels or more restrictive coverage conditions.

For large healthcare companies, this reset is forcing a strategic rethink. Scale alone is no longer enough. Differentiation increasingly depends on evidence, regulatory durability, and control over key steps in care.

Why Debridement Matters

One of the most critical – and least innovated – steps in chronic wound care is debridement: the removal of non-viable tissue so healing can begin. Without effective debridement, downstream treatments often fail, regardless of how advanced they may be.

Despite its importance, enzymatic debridement in the U.S. remains dominated by a single product: collagenase SANTYL ointment, which is estimated to generate more than $360 million in annual U.S. sales. No new FDA-approved enzymatic debridement drugs for chronic wounds have been introduced in decades.

MediWound’s EscharEx is designed to change that. EscharEx is a bromelain-enriched proteolytic enzyme therapy developed to selectively and rapidly remove necrotic tissue, preparing wounds to heal without surgery.

In a randomized Phase 2 study published in The Lancet’s eClinicalMedicine, 63% of patients treated with EscharEx achieved complete debridement within two weeks, compared with 13% for non-surgical standard of care. Median time to complete debridement was nine days for EscharEx versus approximately two months for comparator treatments. In a small head-to-head subgroup analysis against SANTYL, complete debridement at two weeks was achieved in 63% of EscharEx-treated patients versus 0% in the SANTYL arm, though that comparator group included only eight patients.

These results positioned EscharEx not as a marginal improvement, but as a potential reset for a category that has seen little therapeutic progress for decades.

A Late-Stage Asset in a Narrowing Field

In February 2025, MediWound initiated its global Phase 3 VALUE trial, enrolling approximately 216 patients across around 40 sites in the U.S. and Europe. An interim analysis is expected in the second half of 2026. To support execution, the company established research collaborations with leading wound care players including Solventum, Mölnlycke, MIMEDX, Essity, Coloplast and Convatec for its venous leg ulcer and diabetic foot ulcer programs.

Importantly, EscharEx is being developed under a Biologics License Application pathway and is based on a bromelain-enriched enzyme platform consistent with MediWound’s FDA-approved burn treatment, NexoBrid. An independent consulting firm has estimated a peak sales opportunity of approximately $831 million.

In a market increasingly shaped by reimbursement discipline, this combination—late-stage clinical validation, a higher-barrier regulatory pathway, and control over a bottleneck step in care – is becoming harder to find.

Why the Strategic Context Matters Now

Medline’s IPO does not automatically translate into consolidation or acquisitions. But it does signal something important: capital is again willing to back scaled healthcare platforms, and those platforms will be judged not just on breadth, but on defensibility.

As reimbursement economics reset, value is migrating away from products that are easy to replicate toward those that are difficult to replace. For large wound care strategics and medtech suppliers, that shift reframes how portfolios are built. Incremental extensions become less attractive. Clinically validated, regulatory-protected assets become more relevant.

In that context, late-stage assets like EscharEx stand out – not because of speculation about outcomes, but because of where they sit in the evolving structure of the market. As regulatory scrutiny tightens and competitive standards rise, the universe of wound care products capable of meeting both clinical and economic demands is narrowing.

Which companies move first remains to be seen. But for healthcare strategics navigating a post-reimbursement-reset landscape, assets that combine evidence, durability, and strategic scarcity may increasingly command attention.

After Medline’s IPO, A $10+ Billion Wound Care Reset Is Underway – and MediWound May Be Uniquely Positioned

As reimbursement tightens and capital returns, clinically validated wound care assets are becoming scarce – and strategically valuable

From Volume to Validation

Why Debridement Matters

A Late-Stage Asset in a Narrowing Field

Why the Strategic Context Matters Now

Subscribe for Similar Reports

Read More from The Finance Herald